首页> 外文OA文献 >A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins
【2h】

A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins

机译:单个突变可将广泛中和抗体的非结合性生殖系样前身转变为针对HIV-1包膜糖蛋白的结合抗体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in natural infection and elicitation of HIV-1 bnAbs has not been achieved by any vaccine candidates. We and others have reported that HIV-1 bnAbs are highly diversified from their germline-like predecessors and the germline-like predecessors of bnAbs lack measurable binding to HIV-1 envelope (Env) glycoproteins, suggesting that Env structures containing the epitopes of bnAbs may not initiate somatic maturation pathway, which may partially explain the rarity of HIV-1 bnAbs. To determine the minimum mutations required for converting non-binding germline-like predecessors to Env-binding antibodies, we started with the bnAb b12 as a prototype and generated six “chimeric” scFv b12 variants by sequentially replacing the heavy chain V-segment (HV), D(J)-segment [HD(J)] in the heavy chain variable region (VH), and the whole light chain variable region (VL) in b12 germline-like predecessor with the mature counterparts. We tested the recombinant scFv variants for binding and neutralizing activities. Results showed that a single point mutation in germline D-segment was enough to convert nonbinding germline-like b12 to an Env-binding antibody. Replacement with either mature HV or mature VL also made the germline-like b12 bind to Env, but none of single segment replacements conferred neutralization ability to the germline antibody. Mature VL in combination with mature HD(J) or mature HV, or both conferred increasing neutralization activity to the germline antibody. However, hybrid scFv, mature VH/germline VL, did not neutralize HIV-1, suggesting the importance of mature VL in neutralizing the virus. These results may have implications for vaccine development.
机译:抗人免疫缺陷病毒(HIV)-1的广泛中和抗体(bnAbs)在自然感染中很少见,尚未通过任何候选疫苗诱导HIV-1 bnAbs。我们和其他人已经报道,HIV-1 bnAbs与它们的种系样前体高度不同,bnAbs的种系样前体缺乏与HIV-1包膜(Env)糖蛋白的可测量结合,这表明包含bnAbs表位的Env结构可能不能启动体细胞成熟途径,这可能部分解释了HIV-1 bnAb的稀有性。为了确定将非结合性生殖系样前体转化为Env结合抗体所需的最小突变,我们从bnAb b12作为原型开始,并通过顺序替换重链V段(HV)产生了六个“嵌合” scFv b12变体。 ),重链可变区(VH)中的D(J)段[HD(J)]和b12种系样前身中具有成熟对应物的整个轻链可变区(VL)。我们测试了重组scFv变体的结合和中和活性。结果表明,种系D段中的单点突变足以将非结合性种系样b12转换为Env结合抗体。用成熟的HV或成熟的VL替换也使种系样b12与Env结合,但是单节替换均不赋予种系抗体中和能力。成熟的VL与成熟的HD(J)或成熟的HV或两者结合可提高种系抗体的中和活性。但是,杂种scFv,成熟的VH /种系VL不能中和HIV-1,这表明成熟的VL在中和病毒中的重要性。这些结果可能对疫苗开发有影响。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号